DARA Biosciences, Inc.
) recently entered into an exclusive distribution agreement with
Seyer Pharmatec Inc. to sell and distribute the breast cancer
product Soltamox in the Commonwealth of Puerto Rico. The company
intends to launch Soltamox later in the year.
Soltamox is the first and only oral liquid formulation for
breast cancer to be approved by the US Food & Drug
Administration (FDA). Soltamox is marketed in the US by DARA.
License to sell Soltamox in the US was granted by Rosemont
We note that many patients suffering from breast cancer face
problems in swallowing pills. So an oral liquid formulation will be
a convenient, comfortable and easy-to-swallow alternative for women
with breast cancer.
In January, this year DARA acquired South Carolina-based
specialty pharmaceutical company, Oncogenerix, Inc. Oncogenerix
held an exclusive license for the US marketing rights to Soltamox
from Rosemont. After Oncogenerix' acquisition DARA now enjoys the
rights to market the product in the US. Rosemont markets Soltamox
in the UK and Ireland.
We remind investors that in June, this year, DARA launched its
first product Bionect which treats skin irritation and burns
associated with radiation therapy. The company introduced the
product for the cancer care market across the US.
An important oncology candidate at DARA is KRN5500 (completed
phase IIa study). The company's pipeline also includes DB959 (type
Currently, we have a Neutral long-term stance on DARA. The
company carries a Zacks #3 Rank (Hold rating) in the short run.
DARA BIOSCIENCS (DARA): Free Stock Analysis
To read this article on Zacks.com click here.